CN Patent

CN105753789B — 奥拉帕尼与尿素的共晶及其制备方法

Assigned to Suzhou Crystal Cloud Medicine Polytron Technologies Inc · Expires 2018-09-25 · 8y expired

What this patent protects

本发明涉及奥拉帕尼和尿素的共晶及其制备方法。具体的，本发明提供共晶晶型A，该晶型其X射线粉末衍射图在2theta值为17.4°±0.2°、20.7°±0.2°、10.5°±0.2°处具有特征峰。本发明提供的共晶与现有奥拉帕尼游离碱晶型比稳定性更好，引湿性更低，溶解度更高。对未来该药物的优化和开发具有重要价值。

USPTO Abstract

本发明涉及奥拉帕尼和尿素的共晶及其制备方法。具体的，本发明提供共晶晶型A，该晶型其X射线粉末衍射图在2theta值为17.4°±0.2°、20.7°±0.2°、10.5°±0.2°处具有特征峰。本发明提供的共晶与现有奥拉帕尼游离碱晶型比稳定性更好，引湿性更低，溶解度更高。对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN105753789B
Jurisdiction
CN
Classification
—
Expires
2018-09-25
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Crystal Cloud Medicine Polytron Technologies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.